Comparison of the pCR Rate and DFS Among Breast Cancer Patients with Different Hormone Receptor and HER2 Statuses.
DFS
HER2-0
HER2-low
hormone receptor
pCR
Journal
Breast cancer (Dove Medical Press)
ISSN: 1179-1314
Titre abrégé: Breast Cancer (Dove Med Press)
Pays: New Zealand
ID NLM: 101591856
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
02
2023
accepted:
27
04
2023
medline:
8
5
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
epublish
Résumé
Recent studies have investigated the features of breast cancer (BC) with low human epidermal growth factor receptor 2 (HER2) expression or HER2-0 expression. However, the results were inconsistent. In this study, we investigated the differences in the pathological complete response (pCR) rate and disease-free survival (DFS) between HER2-low and HER2-0 BC patients and between subgroups. HER2-negative BC patients who received neoadjuvant chemotherapy between January 2013 and December 2019 in our hospital were retrospectively reviewed. First, the pCR rate and DFS were compared between HER2-low and HER2-0 patients and among different hormone receptor (HR) and HER2 statuses. Subsequently, DFS was compared between different HER2 status populations with or without pCR. Finally, a Cox regression model was used to identify the prognostic factors. Overall, 693 patients were selected: 561 were HER2-low, and 132 were HER2-0. Between the two groups, there were significant differences in N stage (P = 0.008) and HR status (P = 0.007). No significant difference in the pCR rate (12.12% vs 14.39%, P = 0.468) or DFS was observed, independent of HR status. HR+/HER2-low patients had a significantly worse pCR rate (P < 0.001) and longer DFS (P < 0.001) than HR-/HER2-low or HER2-0 patients. In addition, a longer DFS was found in HER2-low patients versus HER2-0 patients among those who did not achieve pCR. Cox regression showed that N stage and HR status were prognostic factors in the overall and HER2-low populations, while no prognostic factor was found in the HER2-0 group. This study suggested that HER2 status is not associated with the pCR rate or DFS. Longer DFS was found only among patients who did not achieve pCR in the HER2-low versus HER2-0 population. We speculated that the interaction of HR and HER2 might have played a crucial role in this process.
Sections du résumé
Background
UNASSIGNED
Recent studies have investigated the features of breast cancer (BC) with low human epidermal growth factor receptor 2 (HER2) expression or HER2-0 expression. However, the results were inconsistent. In this study, we investigated the differences in the pathological complete response (pCR) rate and disease-free survival (DFS) between HER2-low and HER2-0 BC patients and between subgroups.
Methods
UNASSIGNED
HER2-negative BC patients who received neoadjuvant chemotherapy between January 2013 and December 2019 in our hospital were retrospectively reviewed. First, the pCR rate and DFS were compared between HER2-low and HER2-0 patients and among different hormone receptor (HR) and HER2 statuses. Subsequently, DFS was compared between different HER2 status populations with or without pCR. Finally, a Cox regression model was used to identify the prognostic factors.
Results
UNASSIGNED
Overall, 693 patients were selected: 561 were HER2-low, and 132 were HER2-0. Between the two groups, there were significant differences in N stage (P = 0.008) and HR status (P = 0.007). No significant difference in the pCR rate (12.12% vs 14.39%, P = 0.468) or DFS was observed, independent of HR status. HR+/HER2-low patients had a significantly worse pCR rate (P < 0.001) and longer DFS (P < 0.001) than HR-/HER2-low or HER2-0 patients. In addition, a longer DFS was found in HER2-low patients versus HER2-0 patients among those who did not achieve pCR. Cox regression showed that N stage and HR status were prognostic factors in the overall and HER2-low populations, while no prognostic factor was found in the HER2-0 group.
Conclusion
UNASSIGNED
This study suggested that HER2 status is not associated with the pCR rate or DFS. Longer DFS was found only among patients who did not achieve pCR in the HER2-low versus HER2-0 population. We speculated that the interaction of HR and HER2 might have played a crucial role in this process.
Identifiants
pubmed: 37153867
doi: 10.2147/BCTT.S407896
pii: 407896
pmc: PMC10162099
doi:
Types de publication
Journal Article
Langues
eng
Pagination
327-335Informations de copyright
© 2023 Jin et al.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMC Med. 2022 Mar 17;20(1):105
pubmed: 35296300
Breast Cancer Res Treat. 2021 Nov;190(1):155-163
pubmed: 34409551
Cancer Treat Rev. 2023 Apr;115:102538
pubmed: 36898351
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
Eur J Cancer. 2022 Nov;176:30-40
pubmed: 36183652
Zhonghua Yi Xue Za Zhi. 2021 Jun 29;101(24):1835-1838
pubmed: 34619851
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
Mod Pathol. 2022 Aug;35(8):1075-1082
pubmed: 35184150
Lancet Oncol. 2021 Aug;22(8):1151-1161
pubmed: 34252375
Breast. 2023 Feb;67:1-7
pubmed: 36535072
Breast Cancer. 2023 May;30(3):364-378
pubmed: 36656510
Arch Pathol Lab Med. 2018 Nov;142(11):1364-1382
pubmed: 29846104
BMC Cancer. 2022 Oct 20;22(1):1081
pubmed: 36266623
J Biol Chem. 2009 May 22;284(21):14029-39
pubmed: 19286655
ACS Nano. 2017 Jan 24;11(1):335-346
pubmed: 27966906
Clin Transl Oncol. 2022 Dec 31;:
pubmed: 36586066
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Breast Cancer Res. 2022 Mar 21;24(1):22
pubmed: 35307014
Lancet Oncol. 2019 Aug;20(8):1124-1135
pubmed: 31257177
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
Breast Cancer Res. 2016 Jan 06;18(1):3
pubmed: 26738606
J Natl Compr Canc Netw. 2022 Jun;20(6):691-722
pubmed: 35714673
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3969-74
pubmed: 10097147
Cureus. 2022 Feb 17;14(2):e22330
pubmed: 35371692
J Clin Oncol. 2020 Jun 10;38(17):1951-1962
pubmed: 32330069
J Clin Oncol. 2021 May 1;39(13):1485-1505
pubmed: 33507815
J Clin Oncol. 2020 Feb 10;38(5):444-453
pubmed: 31821109
J Oncol Pract. 2018 Jul;14(7):437-441
pubmed: 29920138
J Clin Oncol. 2020 Jun 10;38(17):1887-1896
pubmed: 32058843
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15071-6
pubmed: 14614141
Cancer Res. 2018 Jan 15;78(2):422-435
pubmed: 29187405
Front Oncol. 2022 Jun 16;12:906011
pubmed: 35785207
Front Oncol. 2022 Dec 19;12:999716
pubmed: 36605428